{
    "id": 20044,
    "fullName": "KMT2A - MLLT3",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KMT2A-MLLT3 (also referred to as MLL-AF9) results from the fusion of KMT2A and MLLT3, resulting in a gain of function protein that induces cell proliferation and drives tumorigenesis in culture (PMID: 11607819).",
            "references": [
                {
                    "id": 5004,
                    "pubMedId": 11607819,
                    "title": "Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11607819"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4297,
        "geneSymbol": "KMT2A",
        "terms": [
            "KMT2A",
            "ALL-1",
            "CXXC7",
            "HRX",
            "HTRX1",
            "MLL",
            "MLL1",
            "MLL1A",
            "TRX1",
            "WDSTS"
        ]
    },
    "variant": "KMT2A - MLLT3",
    "createDate": "03/23/2016",
    "updateDate": "07/25/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4300,
                "geneSymbol": "MLLT3",
                "terms": [
                    "MLLT3",
                    "AF9",
                    "YEATS3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11497,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 reduced progression and improved survival of a mouse leukemia model expressing KMT2A-MLLT3 (MLL-AF9) (PMID: 25817203).",
            "molecularProfile": {
                "id": 20485,
                "profileName": "KMT2A - MLLT3"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9548,
                    "pubMedId": 25817203,
                    "title": "Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25817203"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5312,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013).",
            "molecularProfile": {
                "id": 20485,
                "profileName": "KMT2A - MLLT3"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5010,
                    "pubMedId": 26627013,
                    "title": "The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11378,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture, and prolonged survival in animal models of mouse KMT2A-MLLT3-positive leukemia (PMID: 27294782).",
            "molecularProfile": {
                "id": 20485,
                "profileName": "KMT2A - MLLT3"
            },
            "therapy": {
                "id": 5966,
                "therapyName": "I-BET151 + SGC0946",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9271,
                    "pubMedId": 27294782,
                    "title": "Functional interdependence of BRD4 and DOT1L in MLL leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27294782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19048,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "KMT2A-MLLT3 fusions are associated with an intermediate prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 20485,
                "profileName": "KMT2A - MLLT3"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11491,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia (AML) cell line and primary AML samples harboring KMT2A-MLLT3 (MLL-AF9) in culture (PMID: 25817203).",
            "molecularProfile": {
                "id": 20485,
                "profileName": "KMT2A - MLLT3"
            },
            "therapy": {
                "id": 6006,
                "therapyName": "MI-503",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9548,
                    "pubMedId": 25817203,
                    "title": "Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25817203"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9763,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413).",
            "molecularProfile": {
                "id": 20485,
                "profileName": "KMT2A - MLLT3"
            },
            "therapy": {
                "id": 5196,
                "therapyName": "IRAK1/4",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7540,
                    "pubMedId": 28065413,
                    "title": "Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28065413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11709,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Abcb1 was identified as the primary mechanism of acquired Pinometostat (EPZ-5676)-resistance in leukemia cell lines harboring KMT2A-MLLT3 (MLL-AF9) fusion in culture (PMID: 28428443).",
            "molecularProfile": {
                "id": 28189,
                "profileName": "KMT2A - MLLT3 ABCB1 over exp"
            },
            "therapy": {
                "id": 2855,
                "therapyName": "Pinometostat",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9714,
                    "pubMedId": 28428443,
                    "title": "Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28428443"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12871,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-8800 inhibited tumor growth in transplant animal models of mouse acute myeloid leukemia cells harboring SRSF2 P95H and KMT2A-MLLT3 (MLL-AF9) while had no effect in SRSF2 wild-type controls (Blood 2016 128:966).",
            "molecularProfile": {
                "id": 28948,
                "profileName": "KMT2A - MLLT3 SRSF2 P95H"
            },
            "therapy": {
                "id": 6685,
                "therapyName": "H3B-8800",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10817,
                    "pubMedId": null,
                    "title": "H3B-8800, an Orally Bioavailable Modulator of the SF3b Complex, Shows Efficacy in Spliceosome-Mutant Myeloid Malignancies",
                    "url": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20485,
            "profileName": "KMT2A - MLLT3",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28189,
            "profileName": "KMT2A - MLLT3 ABCB1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28948,
            "profileName": "KMT2A - MLLT3 SRSF2 P95H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}